Haya Lorberboumgalski

Title: Haya Lorberboumgalski: Innovator in Allergy Treatment

Introduction

Haya Lorberboumgalski is a prominent inventor based in Jerusalem, Israel. She has made significant contributions to the field of allergy treatment through her innovative research and development. Her work focuses on targeted therapies that aim to improve the quality of life for individuals suffering from allergic responses.

Latest Patents

Haya holds a patent for the invention titled "FcεPE chimeric protein for targeted treatment of allergy responses, a method for its production and pharmaceutical compositions containing the same." This invention presents a novel approach to therapy for allergic responses by targeting and eliminating cells that express the FcεRI receptor. The chimeric protein is designed to specifically kill mouse mast cell lines and primary mast cells derived from bone marrow that express this receptor. The invention also includes methods for producing the chimeric protein and pharmaceutical compositions for treating allergic diseases.

Career Highlights

Haya is associated with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Her work has been instrumental in advancing the understanding and treatment of allergies through innovative biotechnological solutions. She has successfully developed a chimeric protein that combines a cell targeting moiety with a cell killing moiety, specifically utilizing the bacterial toxin Pseudomonas exotoxin.

Collaborations

Haya has collaborated with notable colleagues, including Ala Fishman and Shai Yarkoni. These partnerships have contributed to the successful development and application of her innovative research in allergy treatment.

Conclusion

Haya Lorberboumgalski's contributions to the field of allergy treatment through her innovative chimeric protein represent a significant advancement in targeted therapies. Her work continues to pave the way for new solutions in managing allergic responses effectively.